Peripheral Vascular Devices – Market Insights – Latin America

The Latin American PV device market will see increasing penetration of endovascular techniques and increasing uptake of premium-priced products, such as drug-eluting technologies and IVL, as well as a particular focus on procedures treating iliac and lower-limb arteries. Nevertheless, price competition, unfavorable reimbursement, and unwillingness by some clinicians to adopt new technologies will limit revenue growth to some extent.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for PV devices in Latin America from 2019 through 2033.

Uptake of premium-priced technologies will drive growth in the market.

To what degree will DES and DCBs be adopted in Latin America over the forecast period? How will the adoption affect use of other PV stents or PTA balloons, respectively?

How is the adoption of IVL for PV indications going to impact the PV device market?

Recently published positions and guidelines from key organizations are expected to impact the adoption of paclitaxel-eluting devices.

How will the recent FDA letter concerning paclitaxel-based devices affect device choice in Latin America?

What is the current position about paclitaxel-eluting device among physicians? How will these updates affect to other alternative drug-eluting devices in the market?

Endovascular treatment of PVDs is increasing in Latin America.

Which country has the highest penetration of endovascular procedures?

What factors influence the selection of different approaches to perform endovascular procedures among the Latin American countries covered?

Which country will see the highest procedural and market revenue growth?

Most segments in the Latin American PV device market continue to be dominated by large international manufacturers.

Which companies are the leading competitors in each of the PV device segments?

What competitive strategies will help competitors improve their market positions going forward?